Lee Ko Eun, Seo Yeon Jeong, Kim Gi Beom, An Hyo Soon, Song Young Hwan, Kwon Bo Sang, Bae Eun Jung, Noh Chung Il
Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea.
Department of Pediatrics, Seoul National University Boramae Hospital, Seoul, Korea.
Korean Circ J. 2016 Mar;46(2):246-55. doi: 10.4070/kcj.2016.46.2.246. Epub 2016 Mar 21.
Cardiac catheterization is used to diagnose structural heart disease (SHD) and perform transcatheter treatment. This study aimed to evaluate complications of cardiac catheterization and the associated risk factors in a tertiary center over 10 years.
Total 2071 cardiac catheterizations performed at the Seoul National University Children's Hospital from January 2004 to December 2013 were included in this retrospective study.
The overall complication, severe complication, and mortality rates were 16.2%, 1.15%, and 0.19%, respectively. The factors that significantly increased the risk of overall and severe complications were anticoagulant use before procedure (odds ratio [OR] 1.83, p=0.012 and OR 6.45, p<0.001, respectively), prothrombin time (OR 2.30, p<0.001 and OR 5.99, p<0.001, respectively), general anesthesia use during procedure (OR 1.84, p=0.014 and OR 5.31, p=0.015, respectively), and total procedure time (OR 1.01, p<0.001 and OR 1.02, p<0.001, respectively). Low body weight (OR 0.99, p=0.003), severe SHD (OR 1.37, p=0.012), repetitive procedures (OR 1.7, p=0.009), and total fluoroscopy time (OR 1.01, p=0.005) significantly increased the overall complication risk. High activated partial thromboplastin time (OR 1.04, p=0.001), intensive care unit admission state (OR 14.03, p<0.001), and concomitant electrophysiological study during procedure (OR 3.41, p=0.016) significantly increased severe complication risk.
Currently, the use of cardiac catheterization in SHD is increasing and becoming more complex; this could cause complications despite the preventive efforts. Careful patient selection for therapeutic catheterization and improved technique and management during the peri-procedural period are required to reduce complications.
心导管检查用于诊断结构性心脏病(SHD)并进行经导管治疗。本研究旨在评估一家三级医疗中心10年间心导管检查的并发症及相关危险因素。
本回顾性研究纳入了2004年1月至2013年12月在首尔国立大学儿童医院进行的2071例心导管检查。
总体并发症、严重并发症和死亡率分别为16.2%、1.15%和0.19%。显著增加总体和严重并发症风险的因素包括术前使用抗凝剂(比值比[OR]分别为1.83,p = 0.012和OR 6.45,p < 0.001)、凝血酶原时间(OR分别为2.30,p < 0.001和OR 5.99,p < 0.001)、术中使用全身麻醉(OR分别为1.84,p = 0.014和OR 5.31,p = 0.015)以及总手术时间(OR分别为1.01,p < 0.001和OR 1.02,p < 0.001)。低体重(OR 0.99,p = 0.003)、严重SHD(OR 1.37,p = 0.012)、重复手术(OR 1.7,p = 0.009)和总透视时间(OR 1.01,p = 0.005)显著增加总体并发症风险。高活化部分凝血活酶时间(OR 1.04,p = 0.001)、入住重症监护病房状态(OR 14.03,p < 0.001)和术中同时进行电生理检查(OR 3.41,p = 0.016)显著增加严重并发症风险。
目前,SHD中心导管检查的应用正在增加且变得更加复杂;尽管采取了预防措施,但仍可能导致并发症。为减少并发症,需要谨慎选择接受治疗性导管检查的患者,并在围手术期改进技术和管理。